Navigating Relapse in NPM1-Mutated AML: Monitoring and Managing QTc Prolongation During Therapy

Clinical Pearl: Electrolyte abnormalities—particularly hypokalemia and hypomagnesemia and drug-drug interactions—can significantly exacerbate QTc prolongation during acute myeloid leukemia (AML) therapy. Early recognition and correction are essential to safely continue treatment and prevent potentially serious arrhythmias.

Case Presentation

A 58-year-old woman with de novo AML initially presented with an NPM1 mutation. She underwent standard induction chemotherapy with 7+3 chemotherapy regimen (cytarabine + an anthracycline), achieving a complete remission. Following consolidation therapy, MRD (minimal residual disease) testing was negative. 

Fourteen months after completing consolidation, she presented with evidence of disease relapse, including 35% blasts on bone marrow evaluation. At the time of relapse, her Eastern Cooperative Oncology Group performance status was 1, and she was otherwise clinically stable.

Given the presence of an NPM1 mutation, targeted therapeutic approaches were considered in the context of relapsed disease. Treatment options include the FDA-approved agents revumenib and ziftomenib. Both are approved agents with similar mechanisms of action for relapsed/refractory AML with a susceptible NPM1 mutation, but differ in all approved indications, dosing, and safety profiles. The patient began therapy with revumenib and was followed closely monitoring for treatment-related adverse effects, including weekly EKGs for the first 4 weeks per the package insert.

Early Treatment Course

During the second week of therapy on revumenib, the patient reported new-onset dyspnea and palpitations. Vital signs were stable, and she appeared comfortable at rest. Her white blood cell count remained unchanged, and there was no evidence of weight gain or fluid retention.

Evaluation included a chest radiograph, which was unremarkable, and oxygen saturation, which remained within normal limits.

Laboratory studies revealed significant electrolyte abnormalities, including:

• Magnesium: 1.1 mg/dL
• Potassium: 2.8 mEq/L

An electrocardiogram (ECG) demonstrated occasional premature ventricular contractions. Comparison with her baseline ECG revealed QTc prolongation from 440 ms to 500 ms.

Revumenib was subsequently held, given QTc ≥480, potassium ≤3.5 mEq/L, and magnesium ≤1.6 mg/dL. Work-up included review of medications/new medications or supplements to evaluate for drug-drug interactions. Given new onset of dyspnea, differentiation syndrome was also considered in the differential diagnosis and ultimately ruled out.

QTc Challenge During Therapy

QTc prolongation can occur during menin-inhibitor therapy treatment for relapsed AML and may be exacerbated by metabolic disturbances or concomitant medications. In this case, the patient’s marked hypokalemia and hypomagnesemia likely contributed to the observed QTc increase and ventricular ectopy.

From an advanced practitioner perspective, prompt recognition of this pattern is critical. The care team prioritized immediate electrolyte repletion, including intravenous magnesium and potassium supplementation. Cardiac evaluation was initiated, and potential contributors—including concomitant medications and drug–drug interactions—were reviewed.

After correction of the electrolyte abnormalities, the patient’s QTc interval improved to ≤480 ms, and her symptoms resolved. She was able to restart revumenib at the same dose. Ongoing management included scheduled electrolyte monitoring and repeat ECG assessments to ensure cardiac stability during continued therapy.

This case highlights the importance of proactive toxicity monitoring and agent-specific awareness during AML treatment. Advanced practitioners play a key role in identifying early symptoms, risk mitigation, coordinating diagnostic evaluation, and implementing supportive care measures that allow therapy to continue safely.

Discussion

Mutations in NPM1 generally confer a favorable prognosis in acute myeloid leukemia, especially when occurring without high-risk co-mutations. However, relapse risk and treatment decisions depend heavily on additional factors.

Co-mutations matter:

FLT3-ITD (high burden) and adverse genes (e.g., DNMT3A) increase relapse risk

MRD is critical:

• Measurable residual disease (MRD) status is the strongest predictor of relapse
• MRD-negative: Lower risk → chemotherapy consolidation often sufficient
• MRD-positive: High risk → consider escalation (e.g., transplant)

Relapsed AML remains a challenging clinical scenario, particularly in patients with co-occurring molecular mutations that may influence therapeutic decision-making and prognosis. As novel targeted agents enter clinical practice, advanced practitioners are increasingly responsible for understanding, monitoring, and managing treatment-related toxicities.

Cardiac monitoring is particularly important when therapies carry a risk of QTc prolongation. Notably, QTc prolongation represents a key safety distinction among available agents. While QTc prolongation may be a more prominent and dose-limiting toxicity with revumenib (boxed warning, higher rates, stricter initiation threshold, more frequent dose modifications), it is not absent with ziftomenib. This means ECG monitoring is required for both agents. 

Electrolyte abnormalities, which are common in patients undergoing treatment for hematologic malignancies, can significantly amplify this risk. Routine monitoring and early correction of abnormalities can help mitigate complications and maintain treatment continuity. Avoid concomitant use of drugs that prolong QTc, if unavoidable, monitor more frequently.

This case underscores the importance of interprofessional collaboration, including oncology clinicians, pharmacists, and nursing teams, to optimize patient safety and therapeutic outcomes.

Setting Expectations in Relapsed NPM1-Mutated AML: Time to Response and Transfusion Independence

Clinical Pearl: In differentiation-based therapies for acute myeloid leukemia (AML), early persistence of cytopenias and transfusion dependence does not necessarily indicate treatment failure—clinical benefit may emerge gradually over several weeks.

Case Presentation

A 66-year-old man with relapsed AML presented with NPM1-mutated disease following multiple prior lines of therapy. His treatment history included induction chemotherapy with a 7+3 regimen, followed by high-dose cytarabine consolidation, and subsequent salvage therapy at first relapse.

At the time of current relapse, he demonstrated high disease burden, with 42% bone marrow blasts. Laboratory evaluation revealed significant pancytopenia, including:

Hemoglobin: 8.1 g/dL

Platelets: 22 ×10⁹/L

Absolute neutrophil count: 0.4 ×10⁹/L

He was highly transfusion-dependent, requiring two red blood cell (RBC) transfusions per week and weekly platelet transfusions. Based on his molecular profile and relapsed disease status, therapy with an oral menin inhibitor (ziftomenib) was initiated.

Early Treatment Course (Weeks 1–4)

During the first month of therapy, the patient experienced persistent pancytopenia with no immediate improvement in transfusion requirements. He continued to require frequent RBC and platelet support.

He developed mild symptoms, which was promptly recognized as differentiation syndrome: low-grade fever, peripheral edema, and mild dyspnea. This was managed with immediate hold of ziftomenib and administration of corticosteroids, with resolution of symptoms. He was ultimately able to resume treatment at the same dose once symptoms improved. 

A bone marrow evaluation at week 4 demonstrated a reduction in blasts from 42% to 25%, along with evidence of myeloid differentiation.

Intermediate Phase (Weeks 6–8)

By Weeks 6 to 8, gradual clinical improvements became apparent. Platelet counts began to increase slowly, and the frequency of RBC transfusions decreased.

Repeat marrow evaluation Week 4 demonstrated a further reduction in blasts to 8%. Clinically, the patient required RBC transfusions every 10–14 days and less frequent platelet transfusions.

Response Phase (Weeks 10–12)

By Week 12, the patient achieved a complete remission with partial hematologic recovery. Laboratory parameters improved, with hemoglobin stabilized above 9 g/dL and platelet counts exceeding 80 ×10⁹/L.

Notably, the patient achieved both RBC transfusion independence and platelet transfusion independence.

Discussion

This case illustrates the distinct response kinetics associated with differentiation-based therapies in relapsed AML. Both menin inhibitors demonstrate clinically meaningful responses within the first 2–3 months, with most responses occurring by 6 months—supporting the need to continue therapy for an adequate duration before determining efficacy. Unlike conventional cytotoxic approaches, these therapies may produce gradual reductions in blast burden accompanied by delayed hematologic recovery.

Importantly, both menin inhibitors can cause cytopenias, but clinical impact and management may differ. For advanced practitioners, setting appropriate expectations is critical. Early persistence of cytopenias and ongoing transfusion needs should not automatically prompt discontinuation of therapy if there are signs of clinical activity, particularly with agents where count recovery may lag. Understanding these agent-specific differences can help guide monitoring intensity, supportive care, and decision-making around dose adjustments and treatment discontinuation.

Additionally, prompt recognition and management of differentiation syndrome remains an essential component of care. Supportive strategies, including transfusion management and patient education, play a central role during the early phases of treatment.

Patients should also be advised of the risk of developing differentiation syndrome as early as 3 days after the start of therapy and during treatment. Differentiation syndrome is a class effect of menin inhibitors with similar overall incidence across both agents, with both carrying a boxed warning. There are important differences among severity and timing.

Management strategies also differ; revumenib may be continued initially if no severe symptoms, with steroids unless symptoms persist, while ziftomenib guidance is more conservative, recommending immediate interruption at first suspicion of differentiation syndrome.

Patients should be instructed to immediately report any symptoms suggestive of differentiation syndrome to their care team for further evaluation, including: 

• Fever
• Joint or bone pain
• Dizziness
• Shortness of breath or difficulty breathing
• Cough
• Chest pain
• Rapid weight gain
• Rash
• Decreased urinary output
• Swelling in the hands, feet, ankles, or legs

Distinctions between management strategies for differentiation syndrome highlight the need for early recognition, prompt steroid initiation, and agent-specific management to safely navigate this predictable but potentially serious toxicity.